Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (191-200 of 315) with videos related to

Pageof 32
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2022
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitisAndrew Blauvelt, Leon Kircik, Kim A Papp, et al.
Journal of the American Academy of Dermatology|August 10, 2018
Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitisAndrew Blauvelt, Eric L Simpson, Stephen K Tyring, et al.
Clinical and Experimental Dermatology|April 24, 2025
How do atopic dermatitis trialists perceive the HOME Core Outcome Set? - a survey study from the HOME initiativeYuval Gilad, Eric L Simpson, Christian Apfelbacher, et al.
JAMA Dermatology|October 12, 2022
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) InitiativeYael A Leshem, Joanne R Chalmers, Christian Apfelbacher, et al.
Journal of the American Academy of Dermatology|May 6, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|October 30, 2025
Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled AnalysisAmy S Paller, Marjolein de Bruin-Weller, Eric L Simpson, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 9, 2021
Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic studyJonathan I Silverberg, Sebastien Barbarot, Abhijit Gadkari, et al.
Dermatology and Therapy|August 24, 2021
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and OlderEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
The British Journal of Dermatology|April 20, 2022
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitisEric L Simpson, Robert Bissonnette, Amy S Paller, et al.
Pageof 32

Showing results (191-200 of 315) with videos related to

Sort By:
Pageof 32
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2022
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitisAndrew Blauvelt, Leon Kircik, Kim A Papp, et al.
Journal of the American Academy of Dermatology|August 10, 2018
Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitisAndrew Blauvelt, Eric L Simpson, Stephen K Tyring, et al.
Clinical and Experimental Dermatology|April 24, 2025
How do atopic dermatitis trialists perceive the HOME Core Outcome Set? - a survey study from the HOME initiativeYuval Gilad, Eric L Simpson, Christian Apfelbacher, et al.
JAMA Dermatology|October 12, 2022
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) InitiativeYael A Leshem, Joanne R Chalmers, Christian Apfelbacher, et al.
Journal of the American Academy of Dermatology|May 6, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|October 30, 2025
Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled AnalysisAmy S Paller, Marjolein de Bruin-Weller, Eric L Simpson, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 9, 2021
Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic studyJonathan I Silverberg, Sebastien Barbarot, Abhijit Gadkari, et al.
Dermatology and Therapy|August 24, 2021
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and OlderEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
The British Journal of Dermatology|April 20, 2022
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitisEric L Simpson, Robert Bissonnette, Amy S Paller, et al.
Pageof 32